ZEAL — Zealand Pharma A/S Share News
0.000.00%
Last trade - 00:00- DKK16.22bn
- DKK2.17bn
- DKK9.21bn
Brief: Zealand Pharma Announces Positive Topline Results From Phase 1 Trial With ZP9830
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma, Generate Biomedicines Enter Collaboration, License Agreement
Zealand Pharma, Generate strike AI obesity drug deal worth up to $1.2 billion (updated)
Brief: Generate Biomedicines And Zealand Pharma Enter Collaboration And License Agreement To Develop Protein Therapeutics Engineered With Ai For Metabolic Diseases
Zealand Pharma, Generate strike obesity drug deal worth up to $1.2 billion, Bloomberg News reports
Brief: Zealand Pharma Makes Deal With Generate Worth Up To $1.2 Billion - Bloomberg News
Zealand Pharma slides after obesity drug data
Zealand, Roche's obesity drug helps patients lose up to 9.2% weight in mid-stage trial
Brief: Zealand Pharma Announces Positive Phase 2 Zupreme-2 Topline Results For Amylin Analog Petrelintide In People With Overweight Or Obesity And Type 2 Diabetes
Brief: Zealand Pharma: Completion Of Share Buy-Back Program
Zealand Pharma slides as concerns over patients quitting survodutide trials resurface
Zealand Pharma down 9%; analyst flags 18% weight loss drug dropout
Brief: Zealand Pharma Says Survodutide Achieves Up To 13.1% Weight Loss In Phase III Trial
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Zealand Pharma Says Phase 3 Zupreme Trials Expected To Enroll About 7,000 Participants
Brief: Zealand Pharma Initiates Global Phase 3 ZUPREME Program For Petrelintide
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up